Gyre Therapeutics, Inc. (GYRE) Operating cash flow 2016–2025
Gyre Therapeutics, Inc. (GYRE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$1.0MFY2025 · since FY2016: -$18.5M → $1.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.0M | +127.7% |
| FY2024 | -$3.6M | -114.1% |
| FY2023 | $25.9M | +142.5% |
| FY2022 | $10.7M | +112.7% |
| FY2021 | -$83.8M | -52.1% |
| FY2020 | -$55.0M | -26.2% |
| FY2019 | -$43.6M | -52.7% |
| FY2018 | -$28.6M | -43.2% |
| FY2017 | -$19.9M | -7.9% |
| FY2016 | -$18.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Net marginGYRE Gross profitGYRE Gross marginGYRE Operating incomeGYRE Operating marginGYRE Free cash flowGYRE Capital expendituresGYRE Return on equityGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Total liabilitiesGYRE Shareholders’ equityGYRE overview →